Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | Key trials in kidney cancer at ASCO GU 2023

Tian Zhang • 17 Feb 2023
GU Cancers 2023
Genitourinary Cancer Kidney Cancer Cabozantinib
CaboPoint CheckMate 9ER

Tian Zhang, MD, MHS, UT Southwestern Medical Center, Dallas, TX, discusses some of the key clinical trials being presented at ASCO GU 2023, including CheckMate 9ER (NCT03141177) and CaboPoint (NCT03945773). This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tian Zhang

2:05
STARTAR: ADT with apalutamide, radiation therapy and docetaxel in prostate cancer
Tian Zhang • 2 Jun 2023
2:19
What are the latest in ADCs for prostate and bladder cancer?
Tian Zhang • 2 Jun 2023
1:14
Optimizing outcomes in PSA recurrent prostate cancer
Tian Zhang • 2 Jun 2023
0:42
Unmet needs for patients with advanced RCC
Tian Zhang • 17 Feb 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals